CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Medicine, Inc. (NASDAQ:FMI) today announced that the Company will be
added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior
to the market open on Monday, December 22, 2014.
The NASDAQ Biotechnology Index is designed to track the performance of a
set of NASDAQ-listed securities that are classified as either
biotechnology or pharmaceutical according to the Industry Classification
Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. The
NASDAQ Biotechnology Index is the basis for the iShares NASDAQ
Biotechnology Index Fund (NASDAQ:IBB), which seeks investment results
that correspond generally to the price and yield performance, before
fees and expenses, of the NASDAQ Biotechnology Index. In addition,
options based on the iShares NASDAQ Biotechnology Index Fund trade on
various exchanges. For more information about the NASDAQ Biotechnology
Index visit www.nasdaq.com.
About Foundation Medicine
Foundation Medicine (NASDAQ: FMI) is a molecular information company
dedicated to a transformation in cancer care in which treatment is
informed by a deep understanding of the genomic changes that contribute
to each patient's unique cancer. The company's clinical assays,
FoundationOne for solid tumors and FoundationOne Heme for hematologic
malignancies, sarcomas and certain pediatric cancers, provide a fully
informative genomic profile to identify the molecular alterations in a
patient's cancer and match them with relevant targeted therapies and
clinical trials. Foundation Medicine's molecular information platform
aims to improve day-to-day care for patients by serving the needs of
clinicians, academic researchers and drug developers to help advance the
science of molecular medicine in cancer. For more information, please
or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne®
are registered trademarks of Foundation Medicine, Inc.
Pure Communications, Inc.
Foundation Medicine, Inc.
Source: Foundation Medicine, Inc.
News Provided by Acquire Media